Day: July 31, 2020

In the first half of the year, the Utenos Trikotažas Group earned EUR 14.3 million of revenueDuring the first half of 2020, the Utenos Trikotažas textile company group controlled by SBA, sold products and provided services for a total of EUR 14.3 million, i.e. 9% less than during the same period in 2019. The sales revenue of the company Utenos Trikotažas also dropped by 9% totalling EUR 12.5 million. In this difficult period, the sales revenue of Šatrija, producer of functional-technical clothing, shrunk by 10% to EUR 1.7 million.“As a result of changes in operational circumstances due to coronavirus, we urgently re-oriented some manufacturing by focusing on efficiency, strengthened the channels of e-commerce and attracting new customers. Although at the beginning of Q2 we predicted a two-digit drop in sales, during the first half-year...

TREVOSE, Pa., July 31, 2020 (GLOBE NEWSWIRE) — StoneMor Inc. (NYSE: STON) (“StoneMor” or the “Company”), a leading owner and operator of cemeteries and funeral homes, announced today that the Special Committee (the “Special Committee”) of its board of directors (the “Board”) has received an amended proposal (the “Amended Proposal”), from Axar Capital Management, LP (“Axar”) proposing to acquire all of the outstanding shares of common stock of the Company not owned by Axar or its affiliates for $0.80 per share in cash, subject to certain conditions. The key terms of the Amended Proposal were set forth in a letter dated July 28, 2020, a copy of which is attached hereto as Annex A.As previously reported, Axar originally proposed to acquire all of the outstanding shares of common stock of the Company not owned by Axar or its affiliates...

ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in Lexington, KY treated the patient utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems supported by technical and clinical experts from each company using proprietary connectivity technology.The integrated therapeutic approach combines high-resolution, real-time cardiac imaging and mapping from Acutus’ AcQMap system with the precision and stability of Robotic Magnetic Navigation. The integration of these advanced technologies enables physicians to clearly see a patient’s arrhythmia pattern and then reach targets to deliver therapy...

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June 30, 2020.“We are pleased with the progress we are making on advancing programs that target senescent cells to alter the course of diseases of aging,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “The second half of 2020 is a very important period for UNITY, with our topline 12-week Phase 2 data readout from the UBX0101 program in osteoarthritis expected in the third quarter, as well as the commencement of our initial clinical program in ophthalmology later in the second half of the year.”Clinical Program UpdatesOsteoarthritis...

LAVAL, Québec, July 31, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced it has completed its revisions to the pre-specified Statistical Analysis Plan (SAP) for the TRILOGY 2 Phase 3 trial of CaPre, and has filed it with the Food and Drug Administration (FDA).As previously disclosed, the Company, along with the academic Principal Investigator (PI) of the study, Dariush Mozaffarian M.D., Dr.P.H., and external clinical and statistical experts, conducted rigorous post-hoc analysis of TRILOGY 1 data. Analysis...